Clear Perspective Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Clear Perspective Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,000	Closed	-$808K	–	143
2018 Q3	$808K	Hold	2,000	–	–	0.6%	47
2018 Q2	$690K	Buy	+2,000	New	+$626K	0.48%	55

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Clear Perspective Advisors's REGN Position: Q4 2018 in Review

Clear Perspective Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2018, closing a stake of 2,000 shares — an estimated $808K sold.

Clear Perspective Advisors first reported a position in REGN in Q2 2018 and held it in 2 quarters. The position peaked at $808K in Q3 2018. 671 funds tracked by Wall St. Rank hold REGN as of Q4 2018.

Clear Perspective Advisors reported no remaining Regeneron Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Clear Perspective Advisors sold 2,000 Regeneron Pharmaceuticals shares in Q4 2018, an estimated $808K.
Clear Perspective Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2018 and held it in 2 quarters.
Clear Perspective Advisors's Regeneron Pharmaceuticals position peaked at $808K in Q3 2018.
671 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2018.

Based on Clear Perspective Advisors's 13F filing for Q4 2018, filed 4 Feb 2019.